Skip to main content
Publications
Romano (DeMuro) C , Bratlee-Whhitaker E , Hartry A, Mearns E, Taylor J, Taylor G, Callahan L, Monks D, Kremer I, Lappin D, Frangiosa T, Sangodkar S, Herring WL , Gnanasakthy K , Goss D , McLeod L , Edwards T , Poulos C , DiBenedetti D , Paulsen R. Measuring what matters most to people living with Alzheimer's disease and care partners: what matters most quantitative research development . Poster presented at the Alzheimer's Association International Conference (AAIC) 2024; July 31, 2024. Philadelphia, PA.
Romano CD , Slota C , Bratlee-Whitaker E , Edwards T , Herring WL , McLeod L , Callahan L, Bullok K, Raimundo K, Taylor J, Taylor G, Kremer I, Monks D, Lappin D, Frangiosa T, Gnanasakthy K , Goss D , Comer M, Paulsen R, Hartry A, DiBenedetti D . Measuring "What Matters Most™" to individuals living with Alzheimer's disease and care partners: a conceptual model of Alzheimer's disease . Poster presented at the AAIC 2023 Conference; July 16, 2023. Amsterdam, Netherlands.
Fehnel S , Ervin C , McLeod L , Carson RT, Reasner D, Hanlon J, Eremenco S, Coons SJ, PRO Consortium’s Irritable Bowel Syndrome Working Group. Psychometric evaluation of the diary for irritable bowel syndrome symptoms-constipation (DIBSS-C) . Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain.
Strober B, Zhao Y, Herrera V, Wolin D , McLeod L , Eid D , Bello T. Secukinumab provides greater symptom control in psoriasis-related pain, itching, and scaling compared with previous treatments: evidence from a real-world study in the US . Poster presented at the 26th EADV Congress; September 13, 2017. Geneva, Switzerland.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B , McLeod L , Nyirady J, Tyring S. Secukinumab provides better relief from quality-of-life impact than placebo in moderate to severe psoriasis . Poster presented at the 17th Annual Las Vegas Dermatology Seminar & the 13th Annual Psoriasis Forum; November 12, 2016. Las Vegas, NV.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B , McLeod L , Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis . Poster presented at the SDPA 14th Annual Fall Dermatology Conference 2016; November 6, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B , McLeod L , Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis . Poster presented at the 35th Anniversary Fall Clinical Dermatology Conference; October 23, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B , McLeod L , Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis . Poster presented at the Maui Derm NP+ PA Fall 2016; September 29, 2016. Asheville, NC. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Strober B, Jazayeri S, Thaci D, Augustin M, Zhou Y, Gilloteau I, McLeod LD , Sherif B , Herrera V, Nyirady J, Guana A, Lebwohl M. Secukinumab provides faster and more sustained 52-week complete relief from psoriasis-related pain, itching, and scaling than ustekinumab in subjects with moderate-to-severe plaque psoriasis . Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Proctor C, Mcbride D, Balp M-M, McLeod L , Hunter S, Tian H, Khalil S, Hollis K , Maurer M. Comparison of twice-daily and once-daily Urticaria Activity Score: results from the first international burden of illness ASSURE-CSU study in inadequately-controlled chronic spontaneous (idiopathic) urticaria . Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Vender R, Leonardi C, Puig L, Ziv M, Zhou Y, Gilloteau I, Sherif B , McLeod LD , Nyirady J, Guana A, Strober B. Secukinumab provides greater cumulative 52-week skin clearance and quality of life benefit in patients with moderate-to-severe plaque psoriasis than ustekinumab: an area under the curve analysis . Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Lebwohl M, Blauvelt A, Augustin M, Zhao Y, Gilloteau I, Herrera V, Milutinovic M, You R, Mordin M , McLeod L , Strober B. Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling . Poster presented at the 2016 AAD Summer Meeting; July 2016. Boston, MA.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L , Mordin M , Nelson L , Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials . Poster presented at the 15th Annual Caribbean Dermatology Symposium; January 26, 2016. Grand Cayman. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L , Mordin M , Nelson L , Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials . Poster presented at the 12th Annual Maui Derm for Dermatologists 2016 Conference; January 25, 2016. Maui, HI. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L , Mordin M , Nelson L , Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials . Poster presented at the Winter Clinical Dermatology Conference; January 15, 2016. Kauai, HI. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L , Mordin M , Nelson L , Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials . Poster presented at the SDPA 13th Annual Fall Dermatology Conference 2015; November 12, 2015. Orlando, FL. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L , Mordin M , Nelson L , Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the ERASURE and FIXTURE trials . Poster presented at the 16th Annual Las Vegas Dermatology Seminar; November 5, 2015. Las Vegas, NV. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L , Mordin M , Nelson L , Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the erasure and fixture trials . Poster presented at the Fall Clinical Dermatology Conference; October 2015. Las Vegas, NV. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Gottlieb A, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Tran MH, McLeod L , Odom D , Elewski B. Secukinumab in psoriasis: relationship between clinical- and patient-reported outcomes using clinical trial data from the erasure and fixture trials . Poster presented at the Fall Clinical Dermatology Conference; October 2015. Las Vegas, NV. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L , Mordin M , Nelson L , Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the erasure and fixture trials . Poster presented at the 2nd Annual Maui Derm NP+PA Fall 2015 Meeting; September 2015. Washington, DC. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Gottlieb A, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Tran MH, McLeod L , Odom D , Elewski B. Secukinumab in psoriasis: relationship between clinical- and patient-reported outcomes using clinical trial data from the erasure and fixture trials . Poster presented at the 2nd Annual Maui Derm NP+PA Fall 2015 Meeting; September 2015. Washington, DC. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Lebwohl M, Gottlieb A, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod L , Mordin M , Nelson L , Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the psoriasis symptom diary from the erasure and fixture trials . Poster presented at the National Psoriasis Foundation 2015 National Volunteer Conference; July 2015. San Francisco, CA. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Gottlieb A, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Tran MH, McLeod L , Odom D , Elewski B. Secukinumab in psoriasis: relationship between clinical- and patient-reported outcomes using clinical trial data from the ERASURE and FIXTURE trials . Poster presented at the National Psoriasis Foundation 2015 National Volunteer Conference; July 2015. San Francisco, CA. Previously presented at the 73rd Annual Meeting of the American Academy of Dermatology.
Lebwohl M, Gottlieb AB, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod LD , Mordin MM , Nelson LM , Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the Psoriasis Symptom Diary from the ERASURE and FIXTURE trials . Poster presented at the 73rd Annual Meeting of the American Academy of Dermatology; March 20, 2015. San Francisco, CA.
Gottlieb AB, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Tran MH, McLeod L , Odom D , Elewski B. Secukinumab in psoriasis: relationship between clinical- and patient-reported outcomes using clinical trial data from the ERASURE and FIXTURE trials . Poster presented at the 73rd Annual Meeting of the American Academy of Dermatology; March 2015. San Francisco, CA.
Elewski B, Lebwohl M, Strober B, Szepietowski JC, Blauvelt A, Schlessinger J, Nyirady J, Zhao Y, Tran MH, McLeod L , Odom D , Gottlieb AB. Secukinumab in psoriasis: early improvement in patient-reported symptom diary predicts clinical response . Poster presented at the 73rd Annual Meeting of the American Academy of Dermatology; March 2015. San Francisco, CA.
Kontoudis I, Harries M, Mohr P, Grange F, Ehness R, Benjamin L, Siakpere O, Barth J, Stapelkamp C, Pfersch S, McLeod LD , Kaye JA, Wolowacz SE . Economic burden of melanoma in three European countries: a retrospective observational study . Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands.